These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 28153054)

  • 1. Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer's disease pathology modulates cognitive performance.
    Tautvydaitė D; Kukreja D; Antonietti JP; Henry H; von Gunten A; Popp J
    Alzheimers Res Ther; 2017 Feb; 9(1):6. PubMed ID: 28153054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology.
    Tautvydaitė D; Antonietti JP; Henry H; von Gunten A; Popp J
    J Psychiatr Res; 2017 Jul; 90():12-20. PubMed ID: 28213293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
    Portelius E; Zetterberg H; Skillbäck T; Törnqvist U; Andreasson U; Trojanowski JQ; Weiner MW; Shaw LM; Mattsson N; Blennow K;
    Brain; 2015 Nov; 138(Pt 11):3373-85. PubMed ID: 26373605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
    Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
    J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
    Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
    J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
    Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtle Cognitive Impairment and Alzheimer's Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects.
    Haapalinna F; Kokki M; Jääskeläinen O; Hallikainen M; Helisalmi S; Koivisto A; Kokki H; Paajanen T; Penttinen J; Pikkarainen M; Rautiainen M; Soininen H; Solje E; Remes AM; Herukka SK
    J Alzheimers Dis; 2018; 62(1):165-174. PubMed ID: 29439329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project.
    Doorduijn AS; Visser M; van de Rest O; Kester MI; de Leeuw FA; Boesveldt S; Fieldhouse JLP; van den Heuvel EGHM; Teunissen CE; Scheltens P; van der Flier WM; de van der Schueren MAE
    Nutrients; 2019 May; 11(5):. PubMed ID: 31126170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.
    Lodeiro M; Ibáñez C; Cifuentes A; Simó C; Cedazo-Mínguez Á
    J Alzheimers Dis; 2014; 41(1):223-32. PubMed ID: 24595197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer's Disease.
    Racine AM; Clark LR; Berman SE; Koscik RL; Mueller KD; Norton D; Nicholas CR; Blennow K; Zetterberg H; Jedynak B; Bilgel M; Carlsson CM; Christian BT; Asthana S; Johnson SC
    J Alzheimers Dis; 2016 Oct; 54(4):1395-1408. PubMed ID: 27589532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
    Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
    Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
    Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personality Traits are Related to Selective Cognitive Impairment in Early Alzheimer's Disease.
    Rouch I; Padovan C; Pongan E; Boublay N; Laurent B; Dorey JM; Krolak-Salmon P
    J Alzheimers Dis; 2019; 71(4):1153-1162. PubMed ID: 31524166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.